RISER Sources Sought
ID: 75D30124R73168Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFCENTERS FOR DISEASE CONTROL AND PREVENTIONCDC OFFICE OF ACQUISITION SERVICESATLANTA, GA, 30333, USA

NAICS

All Other Professional, Scientific, and Technical Services (541990)

PSC

SUPPORT- PROFESSIONAL: OTHER (R499)
Timeline
  1. 1
    Posted Aug 16, 2024, 12:00 AM UTC
  2. 2
    Updated Aug 20, 2024, 12:00 AM UTC
  3. 3
    Due Sep 17, 2024, 9:00 PM UTC
Description

The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking potential vendors for its Resources for Improvement of Surveillance and Emergency Response (RISER) program through a sources sought notice. The primary objective of this procurement is to enhance the availability and quality of laboratory reagents necessary for public health surveillance and emergency response, including the production of high-quality reference pathogens and the management of reagent distribution. This initiative is critical for supporting CDC's ongoing surveillance activities, vaccine development, and research related to public health issues. Interested parties are encouraged to submit their capabilities by September 17, 2024, and can contact Jennifer Gartzke at xuy7@cdc.gov or 404-498-0020 for further information.

Point(s) of Contact
Files
Title
Posted
Sep 3, 2024, 7:04 AM UTC
The Centers for Disease Control and Prevention (CDC) has issued a sources sought notice to identify potential vendors for its Resources for Improvement of Surveillance and Emergency Response (RISER) program. This initiative aims to enhance the availability and quality of laboratory reagents essential for public health surveillance and emergency responses. Interested parties are invited to submit information regarding their capabilities, including organizational details and capacity to manage project requirements. The main objectives include producing high-quality reference pathogens, overseeing the distribution of reagents, and ensuring compliance with quality standards. The contractor is expected to develop standard operating procedures (SOPs), maintain secure facilities, and operate a user-friendly RISER website for reagent ordering. Additionally, effective inventory and shipping management is crucial for timely delivery of materials, especially in emergencies. The government's market research will help determine procurement methods, potentially benefiting both small businesses and larger organizations. Responses are due by September 17, 2024, emphasizing the importance of robust partnerships in enhancing national public health preparedness and response capabilities.
Lifecycle
Title
Type
RISER Sources Sought
Currently viewing
Sources Sought
Similar Opportunities
Serological Assays for the Detection and Characterization of Influenza Viruses
Health And Human Services, Department Of
The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is soliciting proposals for a contract focused on serological assays for the detection and characterization of influenza viruses. The primary objectives include performing hemagglutination inhibition assays on human serum samples and developing new serology platforms that are comparable to existing methods. This initiative is crucial for enhancing influenza surveillance and vaccine effectiveness studies, addressing ongoing public health challenges. Interested parties must submit a Letter of Interest by 2:00 PM EST on February 7, 2025, and can contact Jennifer Gartzke at jgartzke@cdc.gov or 404-498-0020 for further information.
Request for Information - Centers for Disease Control and Prevention / National Institute of Occupational Safety and Health / World Trade Center Health Program
Health And Human Services, Department Of
The Centers for Disease Control and Prevention (CDC) is issuing a Request for Information (RFI) to gather industry feedback on a draft Performance Work Statement (PWS) related to the operation of a Survivor Clinical Center of Excellence (CCE) for individuals affected by the September 11, 2011 terrorist attacks in the New York metropolitan area. The objective of this procurement is to ensure continued health monitoring and treatment for eligible survivors, with the CDC seeking input on the clarity, completeness, and feasibility of the draft PWS to enhance the potential procurement process. This initiative is critical for providing necessary healthcare services to a vulnerable population, and the feedback received will help refine the evaluation techniques for selecting qualified vendors. Interested parties must submit their feedback to Serina Allingham at xog9@cdc.gov by 12:00 EST on January 31, 2025, and should note that this RFI is for information purposes only and does not constitute a solicitation for proposals.
Pre-Solicitation FY 2025 CDC OS Emerging Public Health Priorities BAA
Health And Human Services, Department Of
The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is preparing to issue a Fiscal Year 2025 Broad Agency Announcement (BAA) for Applied Research aimed at addressing Emerging Public Health Priorities. This initiative seeks innovative research proposals in various areas, including infectious disease surveillance, wastewater surveillance, and substance use disorder recovery, to enhance public health strategies and responses to emerging threats. The BAA will be open for full and open competition, with a tentative issuance date of December 30, 2024, and a due date for concept papers set for January 30, 2025. Interested contractors must ensure they are registered in the System for Award Management (SAM) to be eligible for award, and further details will be available on SAM.gov.
Lateral Flow Assay (LFA) validation and manufacturing
Health And Human Services, Department Of
The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking qualified sources for the validation and manufacturing of lateral flow assays (LFA) aimed at diagnosing HIV antiretroviral usage in point-of-care settings. The CDC requires an established medical device company capable of producing 25,000 lateral flow devices, which will be utilized in pre-clinical and clinical studies, with the contractor responsible for adapting the provided technical design to their production pipeline and optimizing test performance. This initiative is part of the broader effort to enhance HIV prevention and treatment strategies, emphasizing the need for rapid and cost-effective assays to monitor drug levels. Interested parties must submit their responses, including organizational details and relevant project experience, to Mark Wirtz at mag8@cdc.gov by January 31, 2025, at 12:00 p.m. EST, as this notice is for market research purposes only and does not constitute a solicitation for proposals.
FY25 Vaccines for Children
Health And Human Services, Department Of
The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking manufacturers of pediatric vaccines to participate in the FY25 Vaccines for Children (VFC) program through an Indefinite Delivery Indefinite Quantity (IDIQ) contract. This procurement aims to ensure the availability of standard commercial pediatric vaccines for eligible children, enhancing public health initiatives by providing vaccines at prices below those in the commercial marketplace. The VFC program is crucial for immunizing children who are Medicaid-eligible, uninsured, or underinsured, thereby supporting effective immunization practices and improving overall vaccination coverage. Interested manufacturers should contact James Sprigler at zbs6@cdc.gov or 404.498.3879 for further details, as the solicitation outlines specific requirements for compliance with FDA regulations and operational protocols for vaccine orders.
World Trade Center Health Program - Outreach and Education
Health And Human Services, Department Of
The Department of Health and Human Services, through the Centers for Disease Control and Prevention (CDC), is seeking qualified vendors for the World Trade Center (WTC) Health Program's Outreach and Education services. The primary objective is to enhance awareness and participation among underrepresented populations affected by the September 11 attacks, ensuring they receive necessary medical monitoring and treatment. This initiative is crucial as it aims to address the health needs of over 400,000 individuals impacted, of which only about 34% are currently enrolled in the program. Interested parties must submit their capability statements by February 3, 2025, and can direct inquiries to Joseph Jones at zjb2@cdc.gov. The anticipated contract type is Firm Fixed Price, with a performance period from June 1, 2025, to May 31, 2030.
CDC WORLD TRADE CENTER (WTC) HEALTH PROGRAM PHARMACY BENEFITS MANAGER
Health And Human Services, Department Of
The Centers for Disease Control and Prevention (CDC) is seeking qualified vendors to provide Pharmacy Benefits Manager (PBM) services for the World Trade Center (WTC) Health Program, which supports responders and survivors affected by the 9/11 attacks. The procurement aims to operationalize a three-year contract that includes a 12-month implementation period, a peak operational phase, and a transition-out period, all while ensuring compliance with federal regulations and managing pharmacy benefits for a limited healthcare program. The PBM will be responsible for developing a pharmacy network, implementing electronic claims processing systems, conducting audits, and maintaining transparent pricing, among other tasks, to ensure optimal care for enrollees. Interested parties must submit their qualifications by February 14, 2025, and can direct inquiries to Laurie Presley at xnp0@cdc.gov.
Sebia Inc. Hydrasys 2 Reagents for the Department of Laboratory Medicine
Health And Human Services, Department Of
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure Sebia Inc. Hydrasys 2 reagents through a sole-source contract for the Department of Laboratory Medicine. This acquisition aims to secure essential reagent kits, quality control materials, and supplies necessary for electrophoresis testing, which is critical for monitoring patients with B-cell malignancies and central nervous system diseases. The Sebia reagent kits are uniquely designed for compatibility with the existing Sebia Hydrasys 2 analyzers, ensuring high-quality patient care within the Chemistry Service. Interested parties may submit capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by January 31, 2024, at 6:30 AM EST, as this is not a request for quotations.
Hardy Diagnostic Reagents and Supplies
Health And Human Services, Department Of
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract to Hardy Diagnostics for the procurement of culture media and organism supplies necessary for cGMP Sterility Testing Services. The primary objective is to ensure compliance with FDA regulations by utilizing cGMP quality materials that have been rigorously validated, as these supplies are critical for the isolation and identification of pathogens affecting critically ill patients. The contract will cover a base period of twelve months with an option for an additional three months, and interested vendors capable of providing similar products are encouraged to submit capability statements by the specified deadline. For further inquiries, potential respondents may contact Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov.
Milliflex Rapid 2.0
Health And Human Services, Department Of
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking responses for a Sources Sought Notice regarding the acquisition of the Milliflex Rapid 2.0 microbial detection system. This procurement aims to enhance quality control testing for bioburden contamination in pharmaceutical products, necessitating a system that is compatible with the existing Milliflex Oasis filtration pump currently in use. The initiative is critical for ensuring compliance with quality control standards in pharmaceutical manufacturing, thereby bolstering the FDA's capabilities in evaluating rapid microbial detection methods. Interested vendors must submit their responses by January 30, 2024, at 12:00 PM ET, directed to Contract Specialist Iris Johnson at Iris.Johnson1@fda.hhs.gov and Contracting Officer Maria Finan at Linda.Finan@fda.hhs.gov.